Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 49

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 49
---
 litigation proceeding or administrative
action could put one or more of our patents at risk of being invalidated or interpreted narrowly. Our competitors may assert invalidity
on various grounds, including lack of novelty, obviousness or that we were not the first applicant to file a patent application related
to our product. We may elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes before
litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure.

Our competitors, many of which
have made substantial investments in patent portfolios, trade secrets, trademarks and competing technologies, may have applied for or
obtained, or may in the future apply for or obtain, patents or trademarks that may prevent, limit or otherwise interfere with our ability
to make, use, sell and/or export our products or to use our technologies or product names. Moreover, individuals and groups that are non-practicing
entities, commonly referred to as “patent trolls,” purchase patents and other intellectual property assets for the purpose
of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or “invitations
to license,” or may be the subject of claims that our products and business operations infringe or violate the intellectual property
rights of others. The defense of these matters can be time consuming, costly to defend in litigation, divert management’s attention
and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments.

If we fail to execute invention assignment agreements with our employees and contractors involved in the development of intellectual property or are unable to protect the confidentiality of our trade secrets, the value of our products and our business and competitive position could be harmed.

In addition to patent protection,
we also rely on protection of copyright, trade secrets, know-how and confidential and proprietary information. We generally enter into
confidentiality and invention assignment agreements with our employees, consultants and third parties upon their commencement of a relationship
with us. However, we may not enter into such agreements with all employees, consultants and third parties who have been involved in the
development of our intellectual property. In addition, these agreements may not provide meaningful protection against the unauthorized
use or disclosure of our trade secrets or other confidential information, and adequate remedies may not exist